The Clorox Company (NYSE:CLX) Receives $117.93 Average Price Target from Analysts

Shares of The Clorox Company (NYSE:CLX) have been assigned an average rating of “Reduce” from the sixteen analysts that are currently covering the stock, Marketbeat reports. Four analysts have rated the stock with a sell recommendation, eleven have given a hold recommendation and one has issued a buy recommendation on the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $117.9333.

CLX has been the subject of several research analyst reports. Weiss Ratings lowered Clorox from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Wednesday, February 4th. Royal Bank Of Canada set a $132.00 price target on Clorox in a report on Wednesday, February 4th. The Goldman Sachs Group dropped their target price on shares of Clorox from $110.00 to $94.00 and set a “sell” rating for the company in a research report on Wednesday, January 7th. Rothschild & Co Redburn dropped their price objective on shares of Clorox from $120.00 to $115.00 and set a “neutral” rating for the company in a report on Wednesday, November 5th. Finally, JPMorgan Chase & Co. upped their target price on shares of Clorox from $114.00 to $117.00 and gave the stock a “neutral” rating in a research report on Wednesday, February 4th.

Clorox News Summary

Here are the key news stories impacting Clorox this week:

• Positive Sentiment: Clorox paid a $1.24 dividend on Feb. 13, continuing a 48‑year streak of consecutive dividend increases — a strong signal for income investors supporting demand for CLX shares. Clorox’s 5% Yield Dominates Consumer Staples: Can It Continue?
• Positive Sentiment: Coverage pieces highlighting Clorox as a high‑yield, dividend-bearing consumer staple have kept investor interest intact despite near‑term headwinds. Consumer Staples Look Pricey. Consider Clorox and Other High Yielders With Solid Dividends.
• Neutral Sentiment: Q2 was mixed — revenue slightly beat estimates but EPS missed; International and Health & Wellness helped offset weakness in Household and Lifestyle, leaving guidance/forward outlook uncertain. Q2 Deep Dive: Evaluating Clorox’s Financial and Operating Metrics
• Neutral Sentiment: Analysts and commentators are debating valuation after the mixed quarter and ongoing ERP and promotion headwinds — some see buying value after a rebound, others see mixed upside. A Look At Clorox’s Valuation After A Mixed Quarter And Ongoing ERP And Promotion Headwinds
• Neutral Sentiment: Sector context: CLX has outperformed several staples peers year‑to‑date, which supports momentum-oriented buyers even as company‑specific risks persist. P&G Rallies Under New CEO but Lags Rivals, Faces Tariff Challenges
• Negative Sentiment: Margin pressure is a recurring theme — analysts warn a margin squeeze could force changes to Clorox’s capital-return mix (buybacks vs. dividend), which is bearish for total-return expectations. Is Clorox’s (CLX) Margin Squeeze Reshaping Its Capital Return Playbook?
• Negative Sentiment: Barclays reaffirmed a sell rating, keeping downside pressure from investor sentiment and potential selling. Barclays Reaffirms Their Sell Rating on Clorox (CLX)
• Negative Sentiment: RBC Capital left a Hold rating in place, another signal of limited near‑term upside from some institutional investors. RBC Capital Sticks to Its Hold Rating for Clorox (CLX)

Clorox Price Performance

Shares of NYSE:CLX opened at $124.62 on Friday. The company has a 50 day moving average of $107.21 and a 200 day moving average of $113.74. The stock has a market cap of $15.07 billion, a P/E ratio of 20.36, a P/E/G ratio of 0.62 and a beta of 0.59. Clorox has a 12 month low of $96.66 and a 12 month high of $159.04. The company has a current ratio of 0.74, a quick ratio of 0.48 and a debt-to-equity ratio of 71.03.

Clorox (NYSE:CLX) last posted its earnings results on Tuesday, February 3rd. The company reported $1.39 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.43 by ($0.04). The firm had revenue of $1.67 billion during the quarter, compared to analysts’ expectations of $1.64 billion. Clorox had a return on equity of 383.01% and a net margin of 11.17%.The business’s revenue for the quarter was down .8% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.55 earnings per share. As a group, sell-side analysts forecast that Clorox will post 7.15 EPS for the current fiscal year.

Clorox Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, February 13th. Stockholders of record on Wednesday, January 28th will be given a dividend of $1.24 per share. The ex-dividend date is Wednesday, January 28th. This represents a $4.96 annualized dividend and a dividend yield of 4.0%. Clorox’s dividend payout ratio is 81.05%.

Insider Buying and Selling at Clorox

In other news, Director Pierre R. Breber bought 4,000 shares of the company’s stock in a transaction that occurred on Friday, November 21st. The stock was bought at an average price of $104.13 per share, for a total transaction of $416,520.00. Following the transaction, the director directly owned 13,000 shares of the company’s stock, valued at $1,353,690. This represents a 44.44% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.63% of the company’s stock.

Institutional Investors Weigh In On Clorox

A number of hedge funds have recently made changes to their positions in CLX. Invesco Ltd. grew its holdings in shares of Clorox by 138.3% during the 2nd quarter. Invesco Ltd. now owns 3,245,175 shares of the company’s stock valued at $389,648,000 after purchasing an additional 1,883,465 shares during the last quarter. Norges Bank purchased a new stake in Clorox during the second quarter valued at about $190,429,000. Van ECK Associates Corp grew its stake in shares of Clorox by 93.9% during the third quarter. Van ECK Associates Corp now owns 2,709,972 shares of the company’s stock valued at $334,139,000 after buying an additional 1,312,471 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in shares of Clorox by 218.4% in the second quarter. Arrowstreet Capital Limited Partnership now owns 1,249,127 shares of the company’s stock worth $149,983,000 after buying an additional 856,873 shares during the period. Finally, Northwestern Mutual Wealth Management Co. lifted its stake in shares of Clorox by 6,907.9% in the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 749,703 shares of the company’s stock valued at $75,593,000 after acquiring an additional 739,005 shares during the last quarter. 78.53% of the stock is currently owned by institutional investors.

Clorox Company Profile

The Clorox Company is a leading manufacturer and marketer of consumer and professional products designed to help people care for their homes and live healthy, sustainable lives. Its portfolio spans cleaning and household products, food and beverages, water filtration systems and cat litter, serving both retail and institutional customers. The company’s flagship bleach and disinfecting products are well known in the United States and many international markets, where they help prevent the spread of germs in homes, hospitals, schools and businesses.

Clorox’s diverse brand lineup includes liquid bleach and surface cleaners, eco-friendly cleaning tools, food preservation and preparation items, charcoal grills and briquettes, specialty foods and beverages, pet care products and personal care lines.